Wyeth Reports Earnings Results for the 2009 Second Quarter and First Half and Raises Full Year 2009 Guidance
...th's key pharmaceutical franchises PREVNAR ((R)),( ) ENBREL ((R)) (outside the U.S. and Canada) and Nutritional products, along with higher sales of pristiq
((R)), TYGACIL ((R)), TORISEL ((R)) and the Hemophilia family and higher Enbrel alliance revenue. These increases were partially offset by decrease...
Lexapro Loses First-Line Position for the Treatment of Major Depression
Patient-Flow Forecasts Between pristiq
and Effexor XR Need to Take Into Account Reimburse...all patients in our claims database taking Wyeth's pristiq
for major depression, only 2.6 percent took the drug on the first line. Among patients moving to pristiq
from another drug, 13.0 percent had taken Wyeth's ...
Wyeth Reports Earnings Results for the 2009 First Quarter
...key pharmaceutical franchises ENBREL (R) (outside the U.S. and Canada), PREVNAR (R) and Nutritional products, along with new products TYGACIL (R), pristiq
(R) and TORISEL (R), as well as PROTONIX (R). These increases were partially offset by lower ENBREL alliance revenue, due primarily to the 2008...
Wyeth's Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
selling and educational efforts regarding pristiq
for physicians this week.
"We are proud to make pristiq
available as a new treatment option for
"The recommended therapeutic dose of pristiq
is 50 mg once daily. Titration
is not required to ...
More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms
...that could cause actual results
to differ materially from those expressed or implied by such statements. In
particular, there can be no assurance that pristiq
(desvenlafaxine) will be
commercially successful in the highly competitive market for
antidepressants in the United States, or that desvenlafaxine wil...
New Report Provides Insight Into Developments in the Market for Anxiety and Depression Therapies
... of pharmacotherapies for depression. Drugs/Companies mentioned in this report include: Effexor (venlafaxine;
Wyeth), Lexapro (escitalopram; Forest), pristiq
Wyeth), Cymbalta (duloxetine; Lilly), Wellbutrin (bupropion;
GlaxoSmithKline), Valdoxan (agomelatine; Novartis/Servier), bife...
New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
Data Presented for the First Time on 50 mg/Day Dose for PRISTIQ
for the Treatment of Major Depressive Disorder
COLLEGEVILLE, Pa., Dec. 12 /PRNewswire-FirstCall/ -- Wyeth
Pharmaceuticals, a division of Wyeth (NYSE: WYE ), announces that data from
two Phase 3 clinical studies of...
Wyeth Announces Stockholder Approval of Pfizer Merger at 2009 Annual Meeting
...en by continued growth in its core franchises, Enbrel, Prevnar and Nutritionals, and increased contribution from its newer products, Tygacil, Torisel, pristiq
and Relistor. This solid growth is helping to offset the expected declines of products with emerging generic competition. The Company will report it...
FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
...ve disorder (MDD). Wyeth
expects to begin shipping pristiq
to wholesalers beginning in the second
quarter of 2008.
"We are pleased to be able to bring pristiq
to patients," says Bernard
Poussot, President and ...nal
non-clinical toxicity study.
The efficacy of pristiq
as a treatment for depression was established